AmpliMed pockets $5M in second round

AmpliMed has raised $5 million in its second round of venture capital. The oncology drug developer plans to use the money to push its products in clinical development.

"This is an exciting time for the company as our Amplimexon clinical development program is expanding rapidly and we plan to bring additional new drugs into clinical trials in the near future," said Robert A. Ashley, Chairman, president and CEO of AmpliMed. "This funding will help us to continue these efforts as well as research additional late-stage clinical development opportunities."

- read this release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.